| Document |
Document Title |
|
WO/2022/162992A1 |
The present invention addresses the problem of providing a new pharmaceutical composition that can treat a T cell-independent reaction or an early phase reaction (a symptom in an early phase) of an allergic disease.　Examples of the pre...
|
|
WO/2022/163041A1 |
Provided are: an indole-structure-selective reaction agent and an indole-structure-selective crosslinking agent which are capable of selectively modifying, under mild conditions, an indole structure of a molecule (e.g., tryptophan) conta...
|
|
WO/2022/147620A1 |
The present application relates to compounds of Formula (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs...
|
|
WO/2022/140325A1 |
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided...
|
|
WO/2022/129951A1 |
This invention relates to compounds that are agonists of the muscarinic M1 and M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M1 and/or M4 receptors. Also provided are pharmaceutical compositions...
|
|
WO/2022/111683A1 |
The present invention relates to an intermediate of a substituted azabicyclo[3.2.1]octane compound, and a preparation method therefor. Specifically, disclosed in the present invention are an intermediate (the compound of formula (I)), a ...
|
|
WO/2022/094668A1 |
The present disclosure relates to a process for synthesis of heterocyclic methanone compounds, and in particular 3'-substituted, 3-hydroxyl-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-y
l)-thiophen-3-yl]-methanone compounds, and aza-...
|
|
WO/2022/083687A1 |
A class of selenium heterocyclic compounds and an application thereof. Specifically disclosed are a compound represented by formula (II) and a pharmaceutically acceptable salt thereof.
|
|
WO/2022/076703A1 |
The present disclosure provides processes for preparing a crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-na
phthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propane
nitrile and related intermediate comp...
|
|
WO/2022/076717A1 |
The present invention provides crystalline solvate and solvate/hydrate forms of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-na
phthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propane
nitrile, and methods of making and ...
|
|
WO/2022/076714A1 |
The present invention provides amorphous and crystalline hydrate forms of 3-((lR,3s,5S)-3-((7-((5-methyl-lH-pyrazol-3-yl)amino)-l,6-na
phthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propane
nitrile, and methods of making and using ...
|
|
WO/2022/063050A1 |
The present invention relates to a pyrazole compound and a preparation method therefor and a use thereof. In particular, the present invention relates to a compound shown in formula I, a pharmaceutical composition containing same or a ph...
|
|
WO/2022/040259A1 |
The present invention relates to imidazo[1,2-a]pyridine and [1,2,4]triazolo[1, 5-a]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic...
|
|
WO/2022/040260A1 |
The present invention relates to lH-benzo[d]imidazole derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic diseases, such as e.g. liver fibrosis...
|
|
WO/2022/040267A1 |
The present invention relates to 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives of formula (I) or a salt thereof. The present compounds are inhibitors of TLR9 and useful in treating preventing, or slowing fibrotic di...
|
|
WO/2022/014680A1 |
The present invention provides: compounds that have an agonist activity against the orexin receptor type-2 and that are represented by formula (I), (II), (III), and (IV); and pharmaceutically acceptable salts thereof.
|
|
WO/2022/011204A1 |
The present disclosure provides compounds represented by Formula I: A-L-B1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification. Compounds having Formula I are androgen receptor degraders useful ...
|
|
WO/2022/011083A1 |
The disclosure relates to compounds of formula I, which are formyl peptide 2 (FPR2) receptor agonists. The disclosure also provides compositions and methods of using the compounds, for example, for the treatment of atherosclerosis, heart...
|
|
WO/2022/006543A1 |
The present disclosure features compounds e.g. of formula (I-a) and similar compounds e.g. of formulae (l-g), (l-i), (l-j), (III), (lll-a), (III- b) and (IV) disclosed herein and other related compounds, and pharmaceutical compositions t...
|
|
WO/2021/252392A1 |
The present disclosure is directed to FXR agonists, pharmaceutical compositions thereof, and methods of using the same for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, a...
|
|
WO/2021/245427A1 |
One aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein: ring A is a 5 or 6 membered aromatic or heteroaromatic ring, wherein said aromatic or heteroaromatic...
|
|
WO/2021/238908A1 |
The present invention relates to a salt and a crystal form containing a heteroaryl derivative. The present invention specifically relates to a salt and a crystal form comprising a compound of general formula (I), a preparation method, an...
|
|
WO/2021/233461A1 |
The present invention relates to a novel crystal form of a benzothiazole compound and a preparation method therefor. Provided in the present invention are a crystal form A of a compound of formula (I) and a preparation method therefor an...
|
|
WO/2021/215537A1 |
The present invention addresses the problem of providing a 2-heteroarylaminoquinazolinone derivative. The present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof [in the formula, X1 ...
|
|
WO/2021/174176A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2021/172359A1 |
Provided is a novel CDK9 inhibitor prodrug and a liposome that includes the same. The present invention provides a compound represented by formula (1) or a pharmaceutically acceptable salt thereof, and a liposome that includes the same. ...
|
|
WO/2021/174167A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2021/174170A1 |
The present disclosure features compounds and related compositions that, inter alia, modulate nucleic acid splicing, e.g., splicing of a pre-mRNA, as well as methods of use thereof.
|
|
WO/2021/148598A1 |
The present invention relates to a method for the preparation of an N-monofluoroalkyl tropane, a method for the preparation of a trialkyltin tropane, a method for the preparation of an iodinated and/or radioiodinated tropane and the use ...
|
|
WO/2021/141969A1 |
Lipid nanoparticle compositions for delivery of nucleic acids are described. In various embodiments the lipid nanoparticle contains an ionizable lipid of the Formula (I). Methods of using such lipid nanoparticle compositions to achieve t...
|
|
WO/2021/132637A1 |
The present invention addresses the problem of providing a method for producing a high-purity N-dealkylated cyclic secondary amine via a simple and non-turbulent method. An N-dealkylated cyclic secondary amine can be obtained by reacting...
|
|
WO/2021/133280A1 |
The present invention relates to an efficient and industrially advantageous process for the preparation of scopine free base or salts. Said compounds are important intermediates in the synthesis of tiotropium and pharmaceutically accepta...
|
|
WO/2021/104022A1 |
The present invention relates to the field of medicinal chemistry and provides a novel crystalline form of Tropifexor and a preparation method therefor. The crystalline form is crystalline form II. The XRPD pattern of the crystalline for...
|
|
WO/2021/104021A1 |
Provided in the present invention are a new crystal form of Tropifexor and a preparation method therefor, which fall within the field of medicinal chemistry. The crystal form is crystal form I. The XRPD pattern of crystal form I includes...
|
|
WO/2021/064073A1 |
Compounds of the formula (I) wherein the substituents are as defined in claim 1, useful as a pesticides, especially as herbicides.
|
|
WO/2021/059136A1 |
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
|
|
WO/2021/055627A1 |
The invention provides substituted N-heterocyclic carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, ...
|
|
WO/2021/047581A1 |
Disclosed is a hexahydrobenzopyrazole compound shown in formula (I), and a stereoisomer, a pharmaceutically acceptable salt, a solvate, a hydrate, an N-oxide, a prodrug, and a pharmaceutical composition thereof, a preparation method ther...
|
|
WO/2021/046789A1 |
Disclosed are indazole-carboxamide derivatives and use thereof, specifically a class of indazole-carboxamide derivatives and pharmaceutical compositions containing such compounds, which can be used as 5-HT4 receptor agonists, a method fo...
|
|
WO/2021/023805A1 |
The present invention relates to a compound for treatment of a disease or disorder involving depression, erectile dysfunction, anxiety, sexual dysfunction and/or ejaculatory disorders; or a combination thereof.
|
|
WO/2020/219639A1 |
The invention provides compounds of formula (I): (I) or pharmaceutically-acceptable salts thereof, that are inhibitors of Janus kinases and release an active metabolite in vivo. The invention also provides pharmaceutical compositions com...
|
|
WO/2020/201991A1 |
Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoi...
|
|
WO/2020/184670A1 |
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...
|
|
WO/2020/181283A1 |
The invention relates to carboxamide-pyrimidine derivatives of the general formula (I), or a pharmaceutically acceptable salt thereof, and the use of the compounds of the present invention for the treatment of hyperproliferative diseases...
|
|
WO/2020/157691A1 |
Provided herein are novel crystalline forms of a crystalline compound of Formula (I), which modulates the ORL-1 receptor. The crystalline compounds of Formula (I), compositions thereof, and methods of using thereof that are described her...
|
|
WO/2020/156241A1 |
The present invention relates to aromatic ring or heteroaromatic ring compounds, a preparation method therefor and a medical use thereof. Particularly, the present invention relates to a compound as shown in general formula (I) and a pre...
|
|
WO/2020/150385A1 |
The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-nega...
|
|
WO/2020/150372A1 |
The invention is directed to compounds that are active as antibacterial agents. The invention compounds are active against gram-positive and gram-negative bacteria and can be used to treat infections caused by gram-positive and gram-nega...
|
|
WO/2020/142503A1 |
In alternative embodiments, the provided are therapeutic combinations comprising: nucleophilic hydroxyimino-acetamido alkylamine antidotes that cross the blood-brain barrier (BBB) to catalyze the hydrolysis of organophosphate (OP)-inhibi...
|
|
WO/2020/135210A1 |
Disclosed are a substituted aryl compound or pharmaceutically acceptable salts thereof, a stereoisomer, a polymorphic substance, a solvate, a N-oxide, an isotopically labeled compound, a metabolite or a prodrug and a preparation method t...
|
